Table 1.
Descriptive Statistics.
| Mean | Std. Dev. | Minimum | Maximum | |
|---|---|---|---|---|
| Panel A: Product Type (19,910 sessions, 3,341 users) | ||||
| Concentrate | 0.17 | 0.38 | 0 | 1 |
| Edible | 0.05 | 0.21 | 0 | 1 |
| Flower | 0.74 | 0.44 | 0 | 1 |
| Tincture | 0.04 | 0.20 | 0 | 1 |
| Topical | 0.00 | 0.06 | 0 | 1 |
| Panel B: Subspecies (17,197 sessions, 2,996 users) | ||||
| Hybrid | 0.48 | 0.50 | 0 | 1 |
| C. indica | 0.30 | 0.46 | 0 | 1 |
| C. sativa | 0.22 | 0.41 | 0 | 1 |
| Panel C: Combustion Method (16,902 sessions, 2,936) | ||||
| Joint | 0.13 | 0.33 | 0 | 1 |
| Pipe | 0.43 | 0.49 | 0 | 1 |
| Vape | 0.45 | 0.50 | 0 | 1 |
| Panel D: THC (6,958 sessions, 1,260 users) | ||||
| % THC | 28.3 | 22.8 | 0 | 100 |
| THC < 10% | 0.16 | 0.36 | 0 | 1 |
| THC 10–19% | 0.29 | 0.45 | 0 | 1 |
| THC 20–34% | 0.36 | 0.48 | 0 | 1 |
| THC 35%+ | 0.20 | 0.40 | 0 | 1 |
| Panel E: CBD (5,400 sessions, 1,123 users) | ||||
| % CBD | 11.6 | 16.0 | 0 | 100 |
| CBD < 1% | 0.25 | 0.43 | 0 | 1 |
| CBD 1–9% | 0.33 | 0.47 | 0 | 1 |
| CBD 10–34% | 0.34 | 0.47 | 0 | 1 |
| CBD 35%+ | 0.08 | 0.28 | 0 | 1 |
| Panel F: Outcome and Control Variables (19,910 sessions, 3,341 users) | ||||
| Symptom Change | −3.5 | 2.6 | −10 | 9 |
| Starting Symptom Level | 6.0 | 2.2 | 1 | 10 |
| Ending Symptom Level | 2.4 | 2.2 | 0 | 10 |
| Panel G: Side Effects (15,617 sessions, 2,757 users) | ||||
| Any Negative Side Effect | 0.62 | 0.48 | 0.00 | 1.00 |
| % of Negative Side Effects | 0.12 | 0.14 | 0.00 | 0.92 |
| Any Positive Side Effect | 0.95 | 0.23 | 0.00 | 1.00 |
| % of Positive Side Effects | 0.25 | 0.18 | 0.00 | 1.00 |
| Any Context-Specific Side Effect | 0.78 | 0.41 | 0.00 | 1.00 |
| % of Context-Specific Side Effects | 0.22 | 0.20 | 0.00 | 1.00 |
Notes: Nineteen positive, twelve negative, and eleven context-specific side effects were available for selection.